Invention Application
- Patent Title: MAT2A INHIBITORS FOR TREATING MTAP NULL CANCER
- Patent Title (中): MAT2A抑制剂治疗MTAP空癌
-
Application No.: PCT/US2016/064619Application Date: 2016-12-02
-
Publication No.: WO2017096165A1Publication Date: 2017-06-08
- Inventor: MARJON, Katya , CHOE, Sung Eun
- Applicant: AGIOS PHARMACEUTICALS, INC.
- Applicant Address: 88 Sidney Street Cambridge, Massachusetts 02139 US
- Assignee: AGIOS PHARMACEUTICALS, INC.
- Current Assignee: AGIOS PHARMACEUTICALS, INC.
- Current Assignee Address: 88 Sidney Street Cambridge, Massachusetts 02139 US
- Agency: PERDOK, Monique M., Reg. No. 42,989 et al.
- Priority: US62/262,750 20151203; US62/297,572 20160219
- Main IPC: A61K31/015
- IPC: A61K31/015 ; A61K45/00 ; A61K31/505 ; A61P35/00
Abstract:
The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with a MAT2A inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by a MAT2A inhibitor, comprising assessing whether the tumor cell is absent an MTAP gene whereby cells that are MTAP null are sensitive to inhibition by MAT2A inhibitors.
Information query
